Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14331159 | 0.88 | SCN9A (0.46) | EGLN1GRIN2BSCN9AFPR2 | |
| SCHEMBL3480617 | 0.87 | VEGFA (0.48) | EGLN1GRIN2BMAP4K4FYNPIP4K2A | |
| SCHEMBL3485345 | 0.87 | EGLN1 (0.46) | EGLN1CHEK2GRIN2BMAP4K4FYN | |
| SCHEMBL3485404 | 0.86 | PARP1 (0.49) | GRIN2BSCN9A | |
| SCHEMBL3484739 | 0.86 | EGLN1 (0.46) | EGLN1CHEK2GRIN2BMAP4K4FYN | |
| SCHEMBL3484844 | 0.81 | EGLN1 (0.60) | EGLN1CHEK2GRIN2BHPGDSSCN9A | |
| SCHEMBL3485871 | 0.80 | EGLN1 (0.55) | EGLN1CHEK2GRIN2BHPGDSMAP4K4 | |
| SCHEMBL3484981 | 0.78 | EGLN1 (0.47) | EGLN1CHEK2GRIN2BHPGDSMAP4K4 | |
| SCHEMBL31348066 | 0.77 | EGLN1 (0.48) | EGLN1MAP4K4SCN9APIP4K2A | |
| SCHEMBL3041631 | 0.77 | EGLN1 (0.48) | EGLN1MAP4K4SCN9APIP4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885CHEK2 4502/4885GRIN2B 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.